These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 36670555)

  • 1. Organoid Technology and Its Role for Theratyping Applications in Cystic Fibrosis.
    Conti J; Sorio C; Melotti P
    Children (Basel); 2022 Dec; 10(1):. PubMed ID: 36670555
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Therapeutic Approaches in Cystic Fibrosis.
    Fakıoğlu DM; Altun B
    Turk J Pharm Sci; 2020 Dec; 17(6):686-697. PubMed ID: 33389985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Dynamics and Theratyping in Airway and Gut Organoids Reveal R352Q-CFTR Conductance Defect.
    Wong SL; Awatade NT; Astore MA; Allan KM; Carnell MJ; Slapetova I; Chen PC; Setiadi J; Pandzic E; Fawcett LK; Widger JR; Whan RM; Griffith R; Ooi CY; Kuyucak S; Jaffe A; Waters SA
    Am J Respir Cell Mol Biol; 2022 Jul; 67(1):99-111. PubMed ID: 35471184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intestinal organoids for Cystic Fibrosis research.
    de Poel E; Lefferts JW; Beekman JM
    J Cyst Fibros; 2020 Mar; 19 Suppl 1():S60-S64. PubMed ID: 31787574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Laboratory Tools to Predict CFTR Modulator Therapy Effectiveness and to Monitor Disease Severity in Cystic Fibrosis.
    Bacalhau M; Camargo M; Lopes-Pacheco M
    J Pers Med; 2024 Jan; 14(1):. PubMed ID: 38248793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Theratyping in cystic fibrosis.
    Crawford KJ; Downey DG
    Curr Opin Pulm Med; 2018 Nov; 24(6):612-617. PubMed ID: 30124524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in Preclinical In Vitro Models for the Translation of Precision Medicine for Cystic Fibrosis.
    Silva IAL; Laselva O; Lopes-Pacheco M
    J Pers Med; 2022 Aug; 12(8):. PubMed ID: 36013270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cystic fibrosis: toward personalized therapies.
    Ikpa PT; Bijvelds MJ; de Jonge HR
    Int J Biochem Cell Biol; 2014 Jul; 52():192-200. PubMed ID: 24561283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of CFTR modulators for the treatment of cystic fibrosis.
    Lopes-Pacheco M; Pedemonte N; Veit G
    Expert Opin Drug Discov; 2021 Aug; 16(8):897-913. PubMed ID: 33823716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological analysis of CFTR variants of cystic fibrosis using stem cell-derived organoids.
    Chen KG; Zhong P; Zheng W; Beekman JM
    Drug Discov Today; 2019 Nov; 24(11):2126-2138. PubMed ID: 31173911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel opportunities for CFTR-targeting drug development using organoids.
    Dekkers JF; van der Ent CK; Beekman JM
    Rare Dis; 2013; 1():e27112. PubMed ID: 25003014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Theratyping cystic fibrosis
    Sette G; Lo Cicero S; Blaconà G; Pierandrei S; Bruno SM; Salvati V; Castelli G; Falchi M; Fabrizzi B; Cimino G; De Maria R; Biffoni M; Eramo A; Lucarelli M
    Eur Respir J; 2021 Dec; 58(6):. PubMed ID: 34413153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis.
    Ramalho AS; Fürstová E; Vonk AM; Ferrante M; Verfaillie C; Dupont L; Boon M; Proesmans M; Beekman JM; Sarouk I; Vazquez Cordero C; Vermeulen F; De Boeck K;
    Eur Respir J; 2021 Jan; 57(1):. PubMed ID: 32747394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient personalized translational tools in cystic fibrosis to transform data from bench to bed-side and back.
    Arora K; Yang F; Brewington J; McPhail G; Cortez AR; Sundaram N; Ramananda Y; Ogden H; Helmrath M; Clancy JP; Naren AP
    Am J Physiol Gastrointest Liver Physiol; 2021 Jun; 320(6):G1123-G1130. PubMed ID: 33949881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Forskolin-induced Swelling in Intestinal Organoids: An In Vitro Assay for Assessing Drug Response in Cystic Fibrosis Patients.
    Boj SF; Vonk AM; Statia M; Su J; Vries RR; Beekman JM; Clevers H
    J Vis Exp; 2017 Feb; (120):. PubMed ID: 28287550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CFTR modulator theratyping: Current status, gaps and future directions.
    Clancy JP; Cotton CU; Donaldson SH; Solomon GM; VanDevanter DR; Boyle MP; Gentzsch M; Nick JA; Illek B; Wallenburg JC; Sorscher EJ; Amaral MD; Beekman JM; Naren AP; Bridges RJ; Thomas PJ; Cutting G; Rowe S; Durmowicz AG; Mense M; Boeck KD; Skach W; Penland C; Joseloff E; Bihler H; Mahoney J; Borowitz D; Tuggle KL
    J Cyst Fibros; 2019 Jan; 18(1):22-34. PubMed ID: 29934203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis.
    Dekkers JF; Berkers G; Kruisselbrink E; Vonk A; de Jonge HR; Janssens HM; Bronsveld I; van de Graaf EA; Nieuwenhuis EE; Houwen RH; Vleggaar FP; Escher JC; de Rijke YB; Majoor CJ; Heijerman HG; de Winter-de Groot KM; Clevers H; van der Ent CK; Beekman JM
    Sci Transl Med; 2016 Jun; 8(344):344ra84. PubMed ID: 27334259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. rAAV-CFTRΔR Rescues the Cystic Fibrosis Phenotype in Human Intestinal Organoids and Cystic Fibrosis Mice.
    Vidović D; Carlon MS; da Cunha MF; Dekkers JF; Hollenhorst MI; Bijvelds MJ; Ramalho AS; Van den Haute C; Ferrante M; Baekelandt V; Janssens HM; De Boeck K; Sermet-Gaudelus I; de Jonge HR; Gijsbers R; Beekman JM; Edelman A; Debyser Z
    Am J Respir Crit Care Med; 2016 Feb; 193(3):288-98. PubMed ID: 26509335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human Primary Epithelial Cell Models: Promising Tools in the Era of Cystic Fibrosis Personalized Medicine.
    Awatade NT; Wong SL; Hewson CK; Fawcett LK; Kicic A; Jaffe A; Waters SA
    Front Pharmacol; 2018; 9():1429. PubMed ID: 30581387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
    Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
    Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.